Trials / Terminated
TerminatedNCT05194839
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Aristea Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RIST4721 | RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2023-02-13
- Completion
- 2023-03-06
- First posted
- 2022-01-18
- Last updated
- 2023-06-29
- Results posted
- 2023-06-29
Locations
51 sites across 7 countries: United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05194839. Inclusion in this directory is not an endorsement.